본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

Synergistic therapeutic effect of diethylibestrol and CX-4945 in human acute T-lymphocytic leukemia cells
  • 작성일2019-05-09
  • 최종수정일2019-05-09
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 824
Biomedicine & Pharmacotherapy, 2018, 98, 357─363, DOI: https://doi.org/10.1016/j.biopha.2017.12.078

Synergistic therapeutic effect of diethylibestrol and CX-4945 in human acute T-lymphocytic leukemia cells

Jung-Il Jung, Kyeong-Yong Park; Soon Ae Kim; Jiyeon Kim

Abstract

    Human acute T-lymphocytic leukemia (T-ALL) is one of the most commonly diagnosed hematological disorders, and is characterized by poor prognosis and survival rate. Despite the development of new therapeutic approaches, leukemia treatment options remain limited. In this study, we investigated the immunosuppressive and anti-proliferative effects of the synthetic estrogen diethylstilbestrol (DES), both alone and combined with the casein kinase 2 (CK2) inhibitor CX-4945. Our results indicated that DES induced caspase-dependent apoptosis in a human T-ALL cell line (Jurkat cells), while exerting no significant cytotoxicity in normal peripheral blood mononuclear cells (PBMCs). Phytohaemagglutinin and phorbol 12-myristate 13-acetate induced interleukin (IL)-2 production and activation of NF-κB signaling pathways, which were both inhibited by DES. Moreover, DES exerted synergistic effects with CX-4945 on proliferation and IL-2 production in Jurkat cells. Our results demonstrated that DES exerts anti-proliferative and immunosuppressive effects through inhibition of CK2 and the NF-κB signaling pathway in human T-ALL Jurkat cells.



  • 본 연구는 질병관리본부 연구개발과제(과제번호 2018-보건의료생물자원종합관리) 연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund(code 2018-보건의료생물자원종합관리) by Research of Korea Centers for Disease Control and Prevention.


본 공공저작물은 공공누리  출처표시+상업적이용금지+변경금지 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시+상업적이용금지+변경금지" 조건에 따라 이용할 수 있습니다.
TOP